 Allergan Inc. formally rejected a $46 billion unsolicited takeover bid made by Valeant Pharmaceuticals International Inc., saying the proposal substantially undervalues the Botox maker.. Allergan Chief Executive David Pyott defended his company's aggressive research-and- development and sales-and-marketing spending, which he said had enabled Allergan to launch several new products in recent years and increase annual sales by an average of 11% since 2011.  